Xeris Biopharma Holdings, Inc. — Form 8-K Summary
Business Context and Reporting Period
Xeris Biopharma Holdings, Inc. filed a Form 8-K dated March 8, 2023, under Item 2.02 to announce that it issued a press release covering results of operations and business highlights for the three and twelve months ended December 31, 2022.
The filing identifies Xeris as a Delaware corporation headquartered in Chicago, Illinois, with common stock traded on The Nasdaq Global Select Market under the symbol XERS.
Financial Metrics
The filing text provided does not include the referenced press release’s revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics. The filing therefore does not provide clear values for these items.
Material Changes Versus the Prior Comparable Period
The filing does not state specific year-over-year or quarter-over-quarter changes. Any comparative financial information appears to be contained only in Exhibit 99.1, which is not included in the provided text.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide guidance, outlook, management commentary, risk updates, contingencies, or unusual items. It only indicates that these matters may be discussed in the attached earnings press release.
The company stated that the information furnished under Item 2.02, including Exhibit 99.1, is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly specified.
Facts Investors Should Verify
- Obtain and review Exhibit 99.1 for fourth-quarter and full-year 2022 revenue, earnings, cash flow, balance-sheet, and liquidity data.
- Verify the company’s reported operating results against the full annual report for the year ended December 31, 2022.
- Review any 2023 financial guidance, product-performance commentary, and risk disclosures included in the press release or subsequent filings.
- Confirm whether the press release contains non-GAAP measures and reconcile them to the applicable GAAP measures.